SeHCAT (tauroselcholic [75selenium] acid) for the investigation of bile acid diarrhoea in adults: a systematic review and cost-effectiveness analysis
Background: Tauroselcholic [75selenium] acid (SeHCAT™) (GE Healthcare, Chicago, IL, USA) is a radiopharmaceutical that may be useful in diagnosing bile acid diarrhoea. Objectives: To assess the clinical effectiveness and cost-effectiveness of SeHCAT for the investigation of adults with chronic unexp...
Main Authors: | Marie Westwood, Isaac Corro Ramos, Nigel Armstrong, Edyta Ryczek, Hannah Penton, Marscha Holleman, Caro Noake, Maiwenn Al |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2022-11-01
|
Series: | Health Technology Assessment |
Subjects: | |
Online Access: | https://doi.org/10.3310/JTFO0945 |
Similar Items
-
SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis
by: R Riemsma, et al.
Published: (2013-12-01) -
Prevalence of biliary acid malabsorption in patients with chronic diarrhoea of functional characteristics: a prospective study
by: Virginia Flores, et al.
Published: (2021-02-01) -
Congenital diarrhoea in a neonate with hypernatraemia and dehydration
by: Ammara Kaleem, et al.
Published: (2023-10-01) -
A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients
by: Aditi Kumar, et al.
Published: (2022-05-01) -
High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable bowel syndrome-diarrhoea, based on Rome III and Rome IV criteria
by: Mohamed G. Shiha, et al.
Published: (2020-08-01)